Literature DB >> 26643207

Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.

Vivek Appadurai1, Andrea DeBarber2, Pei-Wen Chiang2, Shailendra B Patel3, Robert D Steiner4, Charles Tyler5, Penelope E Bonnen6.   

Abstract

Cerebrotendinous Xanthomatosis (CTX) is a treatable inborn error of metabolism caused by recessive variants in CYP27A1. Clinical presentation varies, but typically includes infant-onset chronic diarrhea, juvenile-onset bilateral cataracts, and later-onset tendinous xanthomas and progressive neurological dysfunction. CYP27A1 plays an essential role in side-chain oxidation of cholesterol necessary for the synthesis of the bile acid, chenodeoxycholic acid, and perturbations in this gene that reduce enzyme activity result in elevations of cholestanol. It is commonly held that CTX is exceedingly rare, but epidemiological studies are lacking. In order to provide an accurate incidence estimate of CTX, we studied the ExAC cohort of ~60,000 unrelated adults from global populations to determine the allele frequency of the 57 variants in CYP27A1 reported pathogenic for CTX. In addition, we conducted bioinformatics analyses on these CTX-causing variants and determined a bioinformatics profile to predict variants that may be pathogenic but have not yet been reported in the CTX patient literature. An additional 29 variants were identified that met bioinformatics criteria for being potentially pathogenic. Incidence was estimated based allele frequencies of pathogenic CTX variants plus those determined to be potentially pathogenic. One variant, p.P384L, previously reported in three unrelated CTX families had an allele frequency ≥ 1% in European, Latino and Asian populations. Three additional mutations had a frequency of ≥ 0.1% in Asian populations. CTX disease incidence was calculated excluding the high frequency p.P384L and separately using a genetic paradigm where this high frequency variant only causes classic CTX when paired in trans with a null variant. These calculations place CTX incidence ranging from 1:134,970 to 1:461,358 in Europeans, 1:263,222 to 1:468,624 in Africans, 1:71,677 to 1:148,914 in Americans, 1:64,267 to 1:64,712 in East Asians and 1:36,072 to 1:75,601 in South Asians. This work indicates CTX is under-diagnosed and improved patient screening is needed as early intervention prevents disease progression.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Bile acids; Bioinformatics; CDCA; CTX; Cataract; Cholestanol; Cholic acid; IEM; Incidence; Population genetics; Sterol; Xanthoma

Mesh:

Substances:

Year:  2015        PMID: 26643207      PMCID: PMC4767010          DOI: 10.1016/j.ymgme.2015.10.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  14 in total

1.  Clinical imaging and neuropathological correlations in an unusual case of cerebrotendinous xanthomatosis.

Authors:  D Wallon; L Guyant-Maréchal; A Laquerrière; R A Wevers; O Martinaud; L A J Kluijtmans; H G Yntema; P Saugier-Veber; D Hannequin
Journal:  Clin Neuropathol       Date:  2010 Nov-Dec       Impact factor: 1.368

2.  Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized.

Authors:  Matthew T Lorincz; Shirley Rainier; Donald Thomas; John K Fink
Journal:  Arch Neurol       Date:  2005-09

3.  Why screen newborns for profound and partial biotinidase deficiency?

Authors:  Barry Wolf
Journal:  Mol Genet Metab       Date:  2015-01-24       Impact factor: 4.797

4.  Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis.

Authors:  A Verrips; L H Hoefsloot; G C Steenbergen; J P Theelen; R A Wevers; F J Gabreëls; B G van Engelen; L P van den Heuvel
Journal:  Brain       Date:  2000-05       Impact factor: 13.501

5.  A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Gian Nicola Gallus; Maria Teresa Dotti; Antonio Federico
Journal:  J Inherit Metab Dis       Date:  2014-01-18       Impact factor: 4.982

6.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

7.  Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.

Authors:  Gilad Yahalom; Rakefet Tsabari; Noa Molshatzki; Lilach Ephraty; Hofit Cohen; Sharon Hassin-Baer
Journal:  Clin Neuropharmacol       Date:  2013 May-Jun       Impact factor: 1.592

8.  Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance.

Authors:  Penelope E Bonnen; John W Yarham; Arnaud Besse; Ping Wu; Eissa A Faqeih; Ali Mohammad Al-Asmari; Mohammad A M Saleh; Wafaa Eyaid; Alrukban Hadeel; Langping He; Frances Smith; Shu Yau; Eve M Simcox; Satomi Miwa; Taraka Donti; Khaled K Abu-Amero; Lee-Jun Wong; William J Craigen; Brett H Graham; Kenneth L Scott; Robert McFarland; Robert W Taylor
Journal:  Am J Hum Genet       Date:  2013-08-29       Impact factor: 11.025

9.  Identifying a high fraction of the human genome to be under selective constraint using GERP++.

Authors:  Eugene V Davydov; David L Goode; Marina Sirota; Gregory M Cooper; Arend Sidow; Serafim Batzoglou
Journal:  PLoS Comput Biol       Date:  2010-12-02       Impact factor: 4.475

10.  A general framework for estimating the relative pathogenicity of human genetic variants.

Authors:  Martin Kircher; Daniela M Witten; Preti Jain; Brian J O'Roak; Gregory M Cooper; Jay Shendure
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

View more
  24 in total

1.  A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios.

Authors:  Frédéric M Vaz; Albert H Bootsma; Willem Kulik; Aad Verrips; Ron A Wevers; Peter C Schielen; Andrea E DeBarber; Hidde H Huidekoper
Journal:  J Lipid Res       Date:  2017-03-17       Impact factor: 5.922

2.  Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment.

Authors:  Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai
Journal:  J Lipid Res       Date:  2018-08-22       Impact factor: 5.922

3.  Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability.

Authors:  Austin Larson; James D Weisfeld-Adams; Tim A Benke; Penelope E Bonnen
Journal:  JIMD Rep       Date:  2016-11-18

4.  Nationwide survey on cerebrotendinous xanthomatosis in Japan.

Authors:  Yoshiki Sekijima; Shingo Koyama; Tsuneaki Yoshinaga; Masayoshi Koinuma; Yuji Inaba
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

5.  Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis.

Authors:  David E Sleat; Erika Gedvilaite; Yeting Zhang; Peter Lobel; Jinchuan Xing
Journal:  Gene       Date:  2016-08-20       Impact factor: 3.688

6.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

7.  A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract.

Authors:  Mohamed S Abdel-Hamid; Mahmoud Y Issa; Ghada A Otaify; Maha S Zaki
Journal:  Metab Brain Dis       Date:  2017-02-22       Impact factor: 3.584

Review 8.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

9.  Familial variability of cerebrotendinous xanthomatosis lacking typical biochemical findings.

Authors:  Adam J Guenzel; Andrea DeBarber; Kimiyo Raymond; Radhika Dhamija
Journal:  JIMD Rep       Date:  2021-01-08

10.  Achilles Tendon Xanthoma and Cholestanol Revealing Cerebrotendinous Xanthomatosis: A New Case Report.

Authors:  Mohamed Ahmed Ghassem; Aziza Mounach; Julien H Djossou; Hamza Toufik; Najlae El Ouardi; Lahsen Achemlal; Ahmed Bezza
Journal:  Case Rep Rheumatol       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.